Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment

BACKGROUND/AIMS: Bortezomib plus melphalan-prednisone (VMP) is a standard treatment for multiple myeloma, particularly for patients who are ineligible for high-dose therapy. However, early discontinuation or treatment modification is often needed owing to adverse events. The aim of this study was to...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Se Ryeon, Choi, Hojoon, Lee, Byung Hyun, Kang, Ka-Won, Yu, Eun Sang, Kim, Dae Sik, Park, Yong, Choi, Chul Won, Kim, Byung Soo, Sung, Hwa Jung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Internal Medicine 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6823557/
https://www.ncbi.nlm.nih.gov/pubmed/30360024
http://dx.doi.org/10.3904/kjim.2018.144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6823557/
https://www.ncbi.nlm.nih.gov/pubmed/30360024
http://dx.doi.org/10.3904/kjim.2018.144

Ejemplares similares